Abstract
With the widespread use of botulinum toxin (BTX) and greater appreciation of its safety, physicians are increasingly aware of potential applications beyond dystonias, spasticity, and cosmetic denervation. Although most applications for BTX have focused on muscular denervation, autonomic denervation is currently being explored for a variety of clinical problems including excessive drooling, gustatory sweating, and hyperlacrimation. This chapter focuses on the role of BTX for uncontrolled salivation and gustatory sweating.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rossetto O, Seveso M, Caccin P, et al. Botulinum neurotoxins are metalloprotease specific for SNARE proteins involved in neuroexocytosis. In: Kreyden OP, Boni R, Burg G, eds. Hyperhidrosis and Botulinum Toxin in Dermatology. Basel: Karger; 2002, pp. 117–125.
Kontis Y, Johns ME. Anatomy and physiology of the salivary glands. In: Bailey BJ, ed. Head and Neck Surgery—Otolaryngology. 3rd ed. New York: Lippincott Williams & Wilkins; 2001, pp. 429–436.
Sullivan PB, Lambert B, Rose M, Ford-Adams M, Johnson A, Griffiths P. Prevalence and severity of feeding and nutritional problems in children with neurological impariement: Oxford Feeding Study. Dev Med Child Neurol 2000;42:613–617.
Harris SR, Purdy AH. Drooling and its management in cerebral palsy. Dev Med Child Neurol 1987;29:807–811.
Tahmassebi JF, Curzon ME. Prevalence of drooling in children with cerebral palsy attending special schools. Dev Med Chil Neurol 2003;45:613–617.
Hyson HC, Johnson A, Jog MS. Survey of sialorrhea in parkinsonian patients in southwestern Ontario. Can J Neurol Sci 2001;28:S46–S47.
Bhidayasiri R, Truong D. Expanding use of botulinum toxin. J Neurol Sci 2005;235:1–9.
Volonte MA, Porta M, Comi G. Clinical assessment of dysphagia in early phases of Parkinson’s disease. Neurol Sci 2002;23:S121–S122.
Glickman S, Deaney CN. Treatment of relative sialorhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. Eur J Neurol 2001;8:567–571.
Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 1988;3:73–78.
Reddihough D, Johnson H, Ferguson E. The role of a saliva control clinic in the management of drooling. J Paediatr Child Health 1992;28:395–397.
Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorhea with glycopyrrolate: a double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154: 1214–1218.
Talmi YP, Finkelstein Y, Zohar Y Reduction of salivary flow with transdermal scopolamine: a four year experience. Otolaryngol Head Neck Surg 1990;103:615–618.
Frederick FJ, Stewart IF. Effectiveness of transtympanic neurectomy in management of sialorrhea occurring in mentally retarded patients. J Otolaryngol 1982; 11:289–292.
Parisir SC, Blitzer A, Binder WA, Friedman WH. Tympanic neurectomy and chorda tympanectomy. Tran AAOO 1978;86:308–321.
Ethunandan M, Macpherson DW. Persistent drooling: treatment by bilateral sbmandibular duct transposition and simultaneous sublingual gland excision. An R Coll Surg Engl 1998;80: 279–282.
Shott SR, Myer CM, Cotton RT. Surgical management of sialorrhea. Otolaryngol Head Neck Surg 1989; 101:47–50.
Mankarious LA, Bottrill IA, Huchzermyer PM, Bailey CM. Long-term follow up of submandibular duct rerouting for the treatment of sialorrhea in the pediatrie population. Otolaryngol Head Neck Surg 1999;120:303–307.
Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int J Raol Oncol Biol Phys 1998;41:1113–1119.
Jongerius PH, van den Hoogen JA, Limbeek J, Gabreels FJ, van Hulst K, Rottevell JJ. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114: 620–627.
Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeurobBloc (botulinum toxin type B) for type A-resistant cervical dystonia. Neurology 1999;53:1431–1438. 135
Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423–1429.
Ellies M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawa R. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope 2004; 114:1856–1860.
Turk-Gonzales M, Odderson IR. Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands. Neurorehabil Neural Repair 2005;19:58–61.
Frey L. Le syndrome du nerf auricuo-temporal. Rev Neurol 1923;2:97–114.
Arad A, Blitzer A. Botulinum toxin in the treatment of autonomic system disorders. Op Tech in Otolaryngol and Head and Neck Surg 2004;15:118–121.
Drobik C, Laskawi R. Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol (Stockh) 1995;115:459–461.
Laskawi R, Schott T, Schroder M. Recurrent pleomorphic adenomas of the arotid gland: Clinical evaluation and long term follow-up. Br J Oral Maxillofac Surg 1998;36:48–51.
Shaw JE, Parker R, Hollis S, Gokal R, Boulton ATM. Gustatory sweating in diabetes mellitus. Diab Med 1996;13:1033–1037.
Kreyden OP, Scheidegger EP. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clinics in Derm 2004;22:40–44.
Sinha UK, Saadat D, Doherty CM, Rice DH. Use of AlloDerm implant to prevent Frey syndrome after parotidectomy. Arch Facial Plast Surg 2003;5:109–112.
May M. Microanatomy and pathophysiology. In: May M, Schaitkin BM, eds. The Facial Nerve. 2nd ed. New York: Thieme; 2000, pp. 57–65.
Urman JD, Bobrove AM. Diabetic gustatory sweating successful treatment with topical glycopyrrolate: report of a case and review of the literature. Arch Intern Med 1999;159:877–878.
Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey’s syndrome Otolaryngol Head Neck Surg 2000; 122:237–240.
Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomie gustatory sweating by botulinum toxin type A. Neurolog 2002;59:1971–1973.
Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997;42:973–975.
Laskawi R, Drobik C, Schonebeck C. Up to date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey’s syndrome). Laryngoscope 1998;108:381–384.
Laccourreye O, Akl E, Gutierrez-Fonseca R, Garcia D, Brasnu D, Bonan B. Recurrent gustatory sweating (Frey Syndrome) after intracutaneous injection of botulinum toxin type A. Arch Otolaryngol Head Neck Surg 1999;125:282–286.
Bjerkhoel A, Trobbe O. Frey’s syndrome: treatment with botulium toxin. J Laryngol Otol 1997;lll:839–844.
Arad-Cohen A, Blitzer A. Botulinum toxin treatment for symptomatic Frey’s syndrome. Otolaryngol Head and Neck Surg 2000;122:237–240.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this chapter
Cite this chapter
Song, P., Schwartz, J.S., Blitzer, A. (2007). Sialorrhea and Frey’s Syndrome. In: Cooper, G. (eds) Therapeutic Uses of Botulinum Toxin. Humana Press. https://doi.org/10.1007/978-1-59745-247-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-247-2_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-914-7
Online ISBN: 978-1-59745-247-2
eBook Packages: MedicineMedicine (R0)